Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM EST
(firmenpresse) - TUSTIN, CA -- (Marketwire) -- 02/09/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, its president and chief executive officer, is scheduled to present at the 14th Annual BIO CEO and Investor Conference in New York on Tuesday, February 14, 2012 at 8:30 AM Eastern Standard Time (EST).
Peregrine's presentation will be webcast live and available for replay until February 28, 2012 at:
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at .
Contact:
Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.02.2012 - 15:00 Uhr
Sprache: Deutsch
News-ID 1081549
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TUSTIN, CA
Phone:
Kategorie:
Trials
Anmerkungen:
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM EST
"
steht unter der journalistisch-redaktionellen Verantwortung von
Peregrine Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
